Charles Riv­er to ex­pand Ire­land man­u­fac­tur­ing site to add Covid-19 vac­cine ca­pac­i­ty

Con­tract re­searcher Charles Riv­er Lab­o­ra­to­ries has tak­en ad­van­tage of the hot man­u­fac­tur­ing mar­ket, ex­tend­ing its CD­MO arm through a flur­ry of merg­ers and ac­qui­si­tions. In a change of pace, it will add on to its al­ready ex­ist­ing Bal­li­na, Ire­land lo­ca­tion, ex­pand­ing its test­ing ca­pa­bil­i­ties in a $9.52 mil­lion deal that will add an­oth­er 90 roles to the team in the next three years.

The deal will ben­e­fit As­traZeneca as Charles Riv­er will pro­vide test­ing and de­ploy­ment of the drug­mak­er’s Covid-19 vac­cine Vaxzevria and flu vac­cine Fluenz, Irish pub­lic broad­cast­ing sta­tion RTE re­ports. The fa­cil­i­ty was es­tab­lished in 1974 and ac­quired by Charles Riv­er in 2002.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER